BioStock: Chordate’s migraine study paves way for planned exit

The final study results from Chordate Medical’s migraine study PM007 demonstrate a statistically significant effect, confirming the German subgroup results presented at the end of September. The study included 140 patients with chronic migraine and the aim was to evaluate the efficacy and safety of the K.O.S. treatment. The patients who received active treatment got a statistically significantly reduced number of monthly headache days compared to those who received sham treatment. No adverse events were reported. BioStock contacted CEO Anders Weilandt for a comment.

Read the interview with Chordate Medical’s CEO Anders Weilandt at biostock.se:

https://www.biostock.se/en/2022/11/chordates-migraine-study-paves-way-for-planned-exit/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se